Dr. Ming is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3400 Spruce Street
2 Rhoads Pavilion
Philadelphia, PA 19104Phone+1 215-662-2737Fax+1 215-349-8339
Education & Training
- University of California (San Francisco)Fellowship, Dermatopathology, 1997 - 1999
- Massachusetts General Hospital/Beth Israel Deaconess Medical Center/Brigham and Women's HospResidency, Dermatology, 1994 - 1997
- Massachusetts General HospitalInternship, Internal Medicine, 1993 - 1994
- Harvard Medical SchoolClass of 1993
Certifications & Licensure
- CA State Medical License 1997 - Present
- PA State Medical License 2000 - 2024
- American Board of Dermatology Dermatology
- American Board of Dermatology Dermatopathology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- Fellow (FAAD) American Academy of Dermatology
Clinical Trials
- Tailored Intervention for Melanoma Patient's Families Start of enrollment: 2005 Aug 01
Publications & Presentations
PubMed
- 15 citationsAssociation of Marital Status With T Stage at Presentation and Management of Early-Stage MelanomaCimarron E. Sharon, Andrew J. Sinnamon, Michael E. Ming, Emily Y. Chu, Douglas L. Fraker
JAMA Dermatology. 2018-05-01 - 23 citationsSurvival Is Not the Only Valuable End Point in Melanoma ScreeningClara Curiel-Lewandrowski, Caroline C. Kim, Susan M. Swetter, Suephy C. Chen, Allan C. Halpern
The Journal of Investigative Dermatology. 2012-05-01 - 83 citationsSkin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy.Mariah M. Johnson, Sancy A. Leachman, Lisa G. Aspinwall, Lee D. Cranmer, Clara Curiel-Lewandrowski
Melanoma Management. 2017-03-01
Journal Articles
- Risk of Subsequent Cutaneous Melanoma in Moderately Dysplastic Nevi Excisionally Biopsied but with Positive Histologic MarginsDouglas Grossman, Vijay Balakrishnan, Laura K Ferris, Geoffrey Lim, Suephy C Chen, Meera Brahmbhatt, Susan M Swetter, Emily Y Chu, Nathaniel Fleming, Caroline C Kim, M..., JAMA
- Timing of Onset of Adverse Cutaneous Reactions Associated with Programmed Cell Death Protein 1 Inhibitor TherapyTara C Mitchell, Michael E Ming, Leo L Wang, Suzanne McGettigan, Emily Y Chu, Lynn Schuchter, JAMA
Press Mentions
- Guidance on the Clinical Understanding and Use of Long‐Acting Injectable Antipsychotics in Schizophrenia: Hong Kong Consensus StatementsFebruary 8th, 2021
- Cancer Patients May Experience Delayed Skin Effects of Anti-PD-1 TherapyJuly 18th, 2018
- Management Strategies of Academic Pigmented Lesion Clinic Directors in the United StatesJanuary 4th, 2018
- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: